Achieve Life Sciences financials
$7.69−0.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating income | -$55.3M | -$39.7M | -$27.8M | -$40.8M | -$33.1M | -$14.8M | -$16.5M | -$12.8M | -$6.6M |
| Net income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M | -$14.7M | -$16.4M | -$12.7M | -$10.6M |
| Net margin | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.25 | $-1.24 | $-1.50 | $-4.00 | $-4.08 | $-5.42 | $-39.76 | $-72.29 | $-441.40 |
| EBITDA | -$54.7M | -$38.8M | -$27.0M | -$40.6M | -$32.8M | -$14.5M | -$16.3M | -$12.5M | -$6.3M |
| Operating cash flow | -$49.5M | -$29.8M | -$24.5M | -$37.6M | -$29.4M | -$13.5M | -$15.2M | -$10.6M | -$9.1M |
| Free cash flow | -$49.5M | -$29.8M | -$24.5M | -$37.6M | -$29.4M | -$13.5M | -$15.3M | -$10.7M | — |
| Diluted shares | 43.6M | 32.1M | 19.8M | 10.6M | 8.1M | 2.7M | 0.4M | 0.2M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.9M | $12.8M | $15.5M | $24.8M | $43.0M | $35.9M |
| Short-term investments | $15.5M | $21.6M | $0.00 | $0.00 | — | — |
| Total debt | $14.9M | $9.8M | $16.7M | $16.1M | $15.0M | $0.00 |
| Total assets | $41.8M | $38.6M | $19.4M | $30.0M | $47.5M | $40.3M |
| Total liabilities | $20.3M | $17.7M | $20.8M | $21.7M | $19.5M | $3.0M |
| Shareholders' equity | $21.5M | $20.9M | -$1.4M | $8.3M | $28.0M | $37.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology